Potential treatment reduces ‘bad’ cholesterol levels by 61 percent
A potential treatment, called alirocumab, revealed a 61 percent reduction in LDL-C compared to placebo at 24 weeks in the Odyssey Long Term trial, Regeneron and Sanofi announced Sunday.
“Across these four trials, alirocumab showed significant and sustained reductions in LDL-C over one year on top of standard-of-care statin therapy across different patient types,” noted Dr. Jennifer Robinson, Director of the Prevention Intervention Center at the University of Iowa. “We are also encouraged by the consistent safety profile across the trials, including in Odyssey Long Term, the largest Phase 3 trial of a PCSK9 inhibitor, with the longest follow-up period reported to date.”
According to WebMD, LDL or low-density lipoproteins (LDL) are the “bad” cholesterol. High levels of LDL-C can collect in your arteries, leading to heart disease. Healthline notes that more than 70 million Americans have high levels of LDL-C. Furthermore, the publication points out that only fifty percent of these people are getting treatment for their condition.
The Odyssey Long Term trial, which includes 2,341 individuals, is structured to assess the long-term safety and efficacy of 150 mg alirocumab every two weeks versus placebo in individuals with high cholesterol levels. Both the alirocumab and placebo group are given statins at a maximally-tolerated dose.
The researchers found that at 24 weeks, there was a 61 percent reduction from baseline in LDL-C levels in the alirocumab group as compared to a one percent increase in the placebo group. At 52 weeks, there was a 57 percent reduction in LDL-C levels in the alirocumab group as compared to a four percent increase in the placebo group.